tg01 vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05638698)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06411691 | Phase 1 | Nov 4, 2024 | Agenus Inc., Department of Defense, Johns Hopkins University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT06015724 | Phase 2 | Dec 31, 2023 | Bristol-Myers Squibb, Georgetown University, Janssen Pharmaceutica NV, Targovax ASA |
| NCT05841550 | Phase 1/Phase 2 (Phase 2) | May 19, 2023 | Targovax ASA, University of Oslo |
| NCT05638698 | Phase 2 | Dec 31, 2022 | Targovax ASA, University of Kansas |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Targovax ASA | For profit | 3 | 0 | 1 | 2022 |
| Agenus Inc. | For profit | 1 | 0 | 1 | 2024 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2023 |
| Department of Defense | Government | 1 | 0 | 1 | 2024 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2023 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Oslo | Academic/Hospital | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1